Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA (2016 - 2026)

Veracyte's EBITDA history spans 14 years, with the latest figure at $37.2 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 790.9% to $37.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.8 million, a 257.93% increase, with the full-year FY2025 number at $57.8 million, up 257.93% from a year prior.
  • EBITDA hit $37.2 million in Q4 2025 for Veracyte, up from $22.9 million in the prior quarter.
  • Over the last five years, EBITDA for VCYT hit a ceiling of $37.2 million in Q4 2025 and a floor of -$41.9 million in Q1 2021.
  • Historically, EBITDA has averaged -$6.6 million across 5 years, with a median of -$8.5 million in 2021.
  • Biggest five-year swings in EBITDA: crashed 555.11% in 2023 and later surged 790.9% in 2025.
  • Tracing VCYT's EBITDA over 5 years: stood at -$12.3 million in 2021, then soared by 56.05% to -$5.4 million in 2022, then crashed by 555.11% to -$35.5 million in 2023, then surged by 111.76% to $4.2 million in 2024, then surged by 790.9% to $37.2 million in 2025.
  • Business Quant data shows EBITDA for VCYT at $37.2 million in Q4 2025, $22.9 million in Q3 2025, and -$5.3 million in Q2 2025.